High-resolution genomic and expression profiling reveals 105 putative amplification target genes in pancreatic cancer

Neoplasia. 2004 Sep-Oct;6(5):432-9. doi: 10.1593/neo.04130.

Abstract

Comparative genomic hybridization (CGH) studies have provided a wealth of information on common copy number aberrations in pancreatic cancer, but the genes affected by these aberrations are largely unknown. To identify putative amplification target genes in pancreatic cancer, we performed a parallel copy number and expression survey in 13 pancreatic cancer cell lines using a 12,232-clone cDNA microarray, providing an average resolution of 300 kb throughout the human genome. CGH on cDNA microarray allowed highly accurate mapping of copy number increases and resulted in identification of 24 independent amplicons, ranging in size from 130 kb to 11 Mb. Statistical evaluation of gene copy number and expression data across all 13 cell lines revealed a set of 105 genes whose elevated expression levels were directly attributable to increased copy number. These included genes previously reported to be amplified in cancer as well as several novel targets for copy number alterations, such as p21-activated kinase 4 (PAK4), which was previously shown to be involved in cell migration, cell adhesion, and anchorage-independent growth. In conclusion, our results implicate a set of 105 genes that is likely to be actively involved in the development and progression of pancreatic cancer.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Cell Line, Tumor
  • Gene Amplification*
  • Gene Expression Profiling
  • Gene Expression Regulation, Neoplastic
  • Genomics / methods
  • Humans
  • Oligonucleotide Array Sequence Analysis
  • Pancreatic Neoplasms / genetics*
  • Pancreatic Neoplasms / metabolism
  • Protein Serine-Threonine Kinases / genetics
  • p21-Activated Kinases

Substances

  • PAK4 protein, human
  • Protein Serine-Threonine Kinases
  • p21-Activated Kinases